Medicamen Biotech Ltd
Incorporated in 1993, Medicamen Biotech Ltd is a research-led pharmaceutical company involved in developing, manufacturing, and marketing generic finished dosage formulations, and Oncology Formulations[1]
- Market Cap ₹ 534 Cr.
- Current Price ₹ 422
- High / Low ₹ 904 / 355
- Stock P/E 37.5
- Book Value ₹ 159
- Dividend Yield 0.24 %
- ROCE 10.6 %
- ROE 8.78 %
- Face Value ₹ 10.0
Pros
- Company is expected to give good quarter
Cons
- Stock is trading at 2.65 times its book value
- The company has delivered a poor sales growth of 4.34% over past five years.
- Company has a low return on equity of 9.63% over last 3 years.
- Dividend payout has been low at 8.80% of profits over last 3 years
- Company has high debtors of 159 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
101 | 64 | 73 | 78 | 67 | 82 | 112 | 123 | 117 | 110 | 115 | 138 | 165 | |
98 | 64 | 68 | 73 | 62 | 71 | 95 | 105 | 99 | 90 | 91 | 113 | 139 | |
Operating Profit | 3 | -0 | 5 | 5 | 6 | 12 | 17 | 17 | 18 | 20 | 24 | 25 | 26 |
OPM % | 3% | -0% | 7% | 6% | 8% | 14% | 15% | 14% | 15% | 18% | 21% | 18% | 16% |
1 | 1 | 1 | 1 | 1 | 0 | 2 | 4 | 2 | 1 | 2 | 2 | 2 | |
Interest | 3 | 4 | 4 | 4 | 4 | 4 | 3 | 1 | 1 | 2 | 2 | 3 | 3 |
Depreciation | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 6 | 6 | 7 |
Profit before tax | -1 | -5 | 0 | 0 | 1 | 6 | 14 | 18 | 17 | 17 | 18 | 17 | 18 |
Tax % | -28% | -1% | 44% | -267% | 32% | 19% | 27% | 31% | 26% | 25% | 18% | 13% | |
-1 | -5 | 0 | 0 | 0 | 5 | 10 | 12 | 12 | 12 | 15 | 15 | 14 | |
EPS in Rs | -1.01 | -5.81 | 0.10 | 0.46 | 0.48 | 4.91 | 8.89 | 10.28 | 10.04 | 10.22 | 12.20 | 11.86 | 11.26 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 12% | 10% | 5% | 10% | 8% | 8% |
Compounded Sales Growth | |
---|---|
10 Years: | 8% |
5 Years: | 4% |
3 Years: | 6% |
TTM: | 33% |
Compounded Profit Growth | |
---|---|
10 Years: | 18% |
5 Years: | 8% |
3 Years: | 7% |
TTM: | 4% |
Stock Price CAGR | |
---|---|
10 Years: | 47% |
5 Years: | -4% |
3 Years: | -7% |
1 Year: | -40% |
Return on Equity | |
---|---|
10 Years: | 11% |
5 Years: | 11% |
3 Years: | 10% |
Last Year: | 9% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 8 | 8 | 9 | 10 | 10 | 11 | 12 | 12 | 12 | 12 | 12 | 13 | 13 |
Reserves | 11 | 7 | 7 | 7 | 8 | 15 | 63 | 75 | 110 | 122 | 136 | 181 | 189 |
14 | 17 | 15 | 21 | 19 | 18 | 14 | 12 | 11 | 19 | 26 | 26 | 29 | |
35 | 33 | 33 | 31 | 23 | 30 | 28 | 38 | 43 | 39 | 52 | 57 | 66 | |
Total Liabilities | 69 | 65 | 65 | 69 | 60 | 73 | 118 | 137 | 176 | 192 | 226 | 277 | 296 |
23 | 23 | 22 | 20 | 19 | 19 | 25 | 24 | 34 | 90 | 92 | 92 | 92 | |
CWIP | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 15 | 40 | 0 | 0 | 0 | 0 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 4 | 6 |
46 | 42 | 42 | 49 | 41 | 54 | 92 | 97 | 100 | 101 | 131 | 180 | 198 | |
Total Assets | 69 | 65 | 65 | 69 | 60 | 73 | 118 | 137 | 176 | 192 | 226 | 277 | 296 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-3 | -2 | 5 | -3 | 6 | 4 | -5 | 4 | 12 | 13 | 5 | -4 | |
-1 | -1 | -1 | 0 | -1 | -2 | -8 | -15 | -39 | -18 | -8 | -8 | |
3 | 2 | -4 | 3 | -5 | -1 | 33 | -4 | 21 | 6 | 4 | 28 | |
Net Cash Flow | -2 | -1 | 1 | -0 | 0 | 0 | 20 | -14 | -6 | 1 | 1 | 17 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 86 | 105 | 102 | 124 | 87 | 114 | 126 | 129 | 137 | 165 | 193 | 159 |
Inventory Days | 63 | 122 | 95 | 95 | 95 | 102 | 77 | 67 | 85 | 28 | 188 | 230 |
Days Payable | 158 | 225 | 209 | 187 | 160 | 165 | 118 | 134 | 160 | 161 | 291 | 232 |
Cash Conversion Cycle | -10 | 1 | -13 | 32 | 22 | 51 | 85 | 62 | 62 | 32 | 91 | 157 |
Working Capital Days | 29 | 50 | 44 | 80 | 83 | 96 | 135 | 151 | 162 | 166 | 207 | 213 |
ROCE % | 6% | -3% | 13% | 12% | 12% | 25% | 25% | 20% | 15% | 13% | 12% | 11% |
Documents
Announcements
- Declaration Under Regulation 31 (4) Of The SEBI (Substantial Acquisition Of Shares And Takeovers) Regulations, 2011 For The Financial Year Ended On March 31, 2024. 1d
- Certificate Pursuant To Regulation 40(9) Of The SEBI (LODR) Regulations, 2015 17 Apr
- Compliance Certificate Under Regulation 7(3) Of The SEBI (LODR) Regulations, 2015 For The Financial Year Ended On March 31, 2024 17 Apr
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
17 Apr - Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter and year ended on March 31, 2024
- Closure of Trading Window 1 Apr
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Business Overview:[1][2][3]
MBL, a subsidiary of Shivalik Rasayan Ltd with 41.6% ownership, is an integrated Pharmaceutical and Life Sciences Solution Provider. They manufacture pharmaceutical formulations, primarily focusing on oncology therapeutics and generics, distributed through wholesale drug distributors and sold to institutional segments such as government and semi-government institutions, and hospitals. Their formulations cover beta-lactam, non-beta-lactam, and cephalosporin drugs for overseas and domestic markets.